Somite.ai is aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies.
Our AI platform, AlphaStem, fuels a virtuous cycle: It creates therapies, generating massive data that further improve the platform, enabling even faster therapy creation with broader applications.
Our founding team includes repeat AI entrepreneur Dr. Micha Breakstone (Chorus.ai acquired for $575m), the head of the Fundamental AI group at MIT, and three Harvard Medical School professors, including the chair of the genetics department. Incorporated in October 2023, we've raised more than $5 million to date.
